SEARCH RESULTS

In the world of health supplements, it used to be enough to offer just vitamins and minerals. But now, consumers demand nootropics and other new categories of supplements that improve mental health, mental performance and achieve “beauty from within”.  

Shanghai Hutchison Pharmaceuticals Ltd is passionate about bringing education to children in rural communities in China. It recently built its 84th library in the country. This repository of learning is in Chengkou, a rural county in the mountains of southwest China and far from the madding crowd. Volunteers from the company were led on this expedition by company president Zhou Junjie.

Zhou made good use of his knowledge of Chinese medicine by conducting a course on traditional Chinese medicines to introduce the concept to children and perhaps inspire them to become healthcare practitioners and to learn more about their Chinese heritage.

Cenovus is contributing C$100,000 to the building of a children’s park. This will provide an inclusive space for residents and visitors alike to interact and build positive experiences in the town of Lamont, Alberta.

“Tawâw” means “Come in, you’re welcome” or “There is always room for one more” in the language of the local Indigenous people, the Cree. The development is part of Cenovus’ commitment to supporting healthy, safe and resilient communities. There will also be several Indigenous elements, including an orange footbridge to emphasise the importance of a safe space for children – the colour orange reflects that every child matters and represents Orange Shirt Day, a Canadian movement established in response to past injustices visited on Indigenous people and especially their children. Indigenous youth artists will also be invited to decorate the space.  

Those suffering from metastatic colorectal cancer will soon have another option that could improve their survival rates and extend their lives. HUTCHMED’s partner, global pharmaceutical firm Takeda, has obtained approval from the US Food and Drug Administration to make FRUZAQLA™ (fruquintinib) available on the US market.

The drug has been approved for use in patients as part of a treatment protocol that gives them another chance when other treatments such as chemotherapy have proven ineffective. The development partnership with Takeda is part of a broader global partnership strategy. Achieving this watershed will trigger the delivery of sales royalties as well as a milestone payment as part of a deal that will total up to US$1.13 billion.  

Scientists are making incredible progress in using vaccines to combat cancer, bringing hope for improved cancer treatments in the future. Researchers at CK Life Sciences are developing vaccines that can slow down the growth and spread of cancer or prevent its recurrence after surgery.

One of their promising vaccines targets two proteins, PD-L1 (programmed death ligand 1) and PRAME (preferentially expressed antigen in melanoma), which are involved in promoting cancer. Normally, the immune system uses T cells to attack cancer cells, but PD-L1 puts the brakes on T cells, preventing them from doing their job. PRAME, on the other hand, promotes cancer cell growth and spread.

CK Life Science’s PD-L1/PRAME dual-targeting vaccine works by stimulating the immune system to produce T cells that can specifically kill cancer cells that have PD-L1 and/or PRAME. It also triggers the production of antibodies that can block PD-L1, allowing the T cells to attack cancer cells more effectively. Additionally, antibodies against PRAME further enhance the killing of cancer cells.

CK Life Sciences presented their innovative research on this vaccine at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, showcasing its potential for treating liver cancer.  

ESDlife’s WeVow lit a fire at the Spark Awards 2023 to win two Gold awards for “Best Promotion Strategy” and “Best Use of Mobile/App”. WeVow is a wedding app that uses AI and data analyses to make life easier for stressed-out couples working on making their big day the best day.

WeVow and a staff engagement app, We+, along with various client projects, have racked up the awards all year long, including the Hong Kong Institute of Marketing Triple Crown Award. The We+ app won Human Resources Online magazine’s Gold for the “Best HR Digital Transformation Strategy”. These are just the highlights of over 15 awards won from those listed plus the Hong Kong Wireless Technology Industry Association, the DigiZ Awards, MOB-Ex Awards, Loyalty and Engagement Awards, Employee Experience Awards and HR Distinction Awards.

Lake Superior is the greatest of the Great Lakes, the huge inland freshwater oceans that stretch into the heart of North America. They are a vital waterway, and at their western extremity lies the Duluth Marine Terminal, fuelled and operated by the Cenovus Superior Refinery. This crucial gateway brings goods into the American heartland at the border of two states, Minnesota and Wisconsin.

Freight moved by water is one of the most energy-efficient forms of transport. The terminal also serves as a major refuelling port for ships carrying essential products such as limestone, grain, cement, salt, wind turbines and other cargo. It provides economic support as a transit port for the region and as a local employer is a vital part of the mid-West economy.  

HUTCHMED has passed key milestones to be accepted for review for use in the US and Europe. The fruquintinib New Drug Application has been accepted by the US Food and Drug Administration (FDA). The FDA has also granted priority review, with the Prescription Drug User Fee Act (PDUFA) date set for 30 November 2023. The Market Authorization Application in Europe has also been validated and accepted for regulator review by the European Medicines Agency. Results of the Phase III FRESCO‑2, a key study that supported the regulatory submissions, were published in The Lancet, one of the world’s most prestigious and well-respected medical journals.  

CK Life Sciences’ Dominion Salt has been a pioneer and industry leader in providing high-quality salt products to customers worldwide for the past seven and a half decades. Dominion Salt started salt production at Lake Grassmere on the northern end of South Island and never looked back. Its Lake Grassmere salt field was New Zealand’s first and remains its only salt field today. Dominion Salt’s diamond anniversary sees it providing a wide range of salt products, from table salt for people and salt licks for animals to pharmaceutical grade sodium chloride.

HUTCHMED has come to a licensing agreement with global pharmaceutical giant Takeda Pharmaceutical to further the global development, commercialisation and manufacture of fruquintinib outside of China. A US$400 million upfront payment and additional potential milestone payments could reach US$1.13 billion upon achieving regulatory, development and commercial sales milestones.  

Shanghai Hutchison Pharmaceuticals has received approval from Health Canada to directly export their Danning Tablets to Canada. The product will be marketed as a licensed natural product in Canada under the brand name Biliflow. It marks not only a step forward for Shanghai Hutchison Pharmaceuticals but also the internationalisation and modernisation of traditional Chinese medicine.  

Canada has always been, and continues to be, a hot destination for immigrants. Cenovus Energy is supporting their resettlement with a C$450,000 grant to local non-governmental organisation (NGO) Immigrant Services Calgary (ISC). The city is home to over 400,000 immigrants and refugees and the strategic partnership with ISC will help direct immigrants to over 50 newcomer-serving partner organisations to help them with employment, education, health and more. Beyond the connection to services, the grant will also support the Immigrants of Distinction Awards gala that celebrates the contribution of immigrants to a strong and prosperous Canada.  

HUTCHMED’s fruquintinib is now targeting second-line gastric cancer. A Phase III study, involving 703 patients, has shown a statistically significant impact in improving progression-free survival (PFS) when combined with another drug, paclitaxel. PFS is the length of time during and after the treatment of a disease wherein a patient lives with the disease but it does not get worse.

HUTCHMED has recently completed patient enrolment of ESLIM-01, the Phase III clinical trial of sovleplenib for the treatment of immune thrombocytopenia (ITP), an autoimmune disorder that can lead to increased risk of bleeding. ITP can often be serious and can have a significant, multifaceted impact on patients’ health and quality of life. Patients often become resistant to treatment over time and new treatment options are desperately needed. The drug has been granted Breakthrough Therapy Designation for ITP in China. It is also being studied for use in indolent non-Hodgkin’s lymphoma and multiple subtypes of B-cell malignancies.

PharusDx, a CK Life Sciences and CK Hutchison investee, is developing a test that would provide fast, accurate diagnosis of not one but multiple types of cancer – all from a single blood sample. And it is using AI to do it.  

HUTCHMED’s global Phase III registration trial of its colorectal cancer-fighting drug, fruquintinib, aims to gain the regulatory approvals needed to bring it to cancer patients around the world. A 14-country study is the next step in bringing new options to doctors and new hope to families struggling with cancer.  

Patient access to novel treatments just got easier in parts of China. HUTCHMED’s surufatinib (SULANDA® in China) has been approved in the Macau Special Administrative Region. This drug has benefited over 12,000 patients with neuroendocrine tumours in China.

HUTCHMED’s first in-licensed product tazemetostat (TAZVERIK®) has been approved for use in Hainan Boao Lecheng International Medical Tourism Pilot Zone under the Clinically Urgently Needed Imported Drugs scheme. TAZVERIK® is a first-in-class EZH2 inhibitor that has been approved by the US Food and Drug Administration (FDA) for the treatment of certain patients with follicular lymphoma and advanced epithelioid sarcoma, a type of blood cancer and soft-tissue cancer, respectively.  

GAMECO, operating out of Guangzhou Baiyun International Airport since 1989, has signed two major agreements with the world-leading aircraft manufacturer, Boeing. A five-year contract will see them cooperate on the first integrated materials management partnership in Mainland China. Boeing will provide demand planning, on-site personnel and logistics services to support GAMECO’s operations to optimise materials purchase and inventory costs.

The other agreement will see the firms work together to expand their cooperation to convert passenger aircraft to freighters to match growing demand for cargo capacity, with B737-800 Boeing Converted Freighters (BCFs) and B767-300 BCFs being adapted. In fact, GAMECO just celebrated re-delivery of the first Boeing B767-300 BCF in Mainland China last month. Boeing forecasts demand for over 1,720 freighter conversions in the next 20 years.  

hutchgo.com celebrates 20 years of transporting people to their heart’s desire. Formerly known as Hutchison-Priceline at inception in 2002, they continue to provide best-in-class service and assistance to travellers with all their heart. Here’s to the next 20 years!

Authorities in the Macau Special Administrative Region have approved the commercialisation of ELUNATE® (fruquintinib). ELUNATE® gained its first approval in Mainland China by the National Medical Products Administration (“NMPA”) in September 2018 for the treatment of metastatic colorectal cancer. It is estimated that more than 40,000 patients have benefited from this novel treatment since its launch. It is the first homegrown innovative oncology drug to be marketed in Macau based on NMPA approval.

A new wave of HUTCHMED innovation is also on the way. In January 2022, sovleplenib was granted Breakthrough Therapy Designation by the NMPA. The designation allows accelerated development of new drugs that treat life-threatening diseases or serious conditions which lack effective treatment options. Sovleplenib has demonstrated encouraging results in patients with immune thrombocytopenia (“ITP”), an autoimmune bleeding disorder that can often have a significant, multifaceted impact on patients’ health and quality of life. It is now being studied in a China Phase III trial on ITP, along with additional studies on lymphoma ongoing in China, the US and Europe.  

China’s National Reimbursement Drug List aims to make life-saving drugs accessible to citizens in Mainland China and has expanded the number of HUTCHMED medicines on the list. The latest to be included is SULANDA® (surufatinib), following its approval for the treatment of advanced pancreatic neuroendocrine tumours. This latest update of the list also renewed ELUNATE® (fruquintinib), first included in 2020, for the treatment of metastatic colorectal cancer.  

Guangzhou Aircraft Maintenance Engineering Company (GAMECO) opened a new aircraft maintenance facility covering an area of over 98,000 square metres, with a roof big enough to accommodate six wide-body and five narrow-body aircraft under its capacious canopy. This increase in capacity will strengthen the Guangzhou airport economic zone as an important national centre for aircraft maintenance, helping China Southern Airlines’ fleet and supporting other customers in the region.  

ESDlife honours those entrusted with the most important day in the lives of young couples in love. Bridal Award 2021 recognised those companies that delivered the utmost in wedding excellence in 2021, ensuring the “big day” was also a perfect one. Thirty-eight awards were presented to outstanding brands and service providers in Hong Kong.

HUTCHMED is now a constituent stock in the FTSE Russell’s Global Equity Index Series (GEIS), including FTSE All-World, FTSE Global All Cap, FTSE Global Total Cap and FTSE Global Mid Cap Indexes. The GEIS monitors more than 16,000 stocks in over 70 countries representing 98% of global market cap, making it a key indicator of global stock market direction.  

HUTCHMED is the new brand for the innovative biopharmaceutical business formerly known as Hutchison China MediTech. The company recently launched a successful listing on the Stock Exchange of Hong Kong (adding to its London AIM and Nasdaq presence), under the venerable stock code 13, which had been held by Hutchison Whampoa. It is now included in over 10 indexes including the Hang Seng Composite Index, the main board listing in Hong Kong, in addition to the Hang Seng Healthcare Index, and the Hang Seng Hong Kong-Listed Biotech Index. Mainland investors also have access to the stock through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programmes.  

Orpathys® (savolitinib, for lung cancer) and Sulanda® (surufatinib, for neuroendocrine tumours) have both been approved for use and then launched in Mainland China this year. Both drugs are unique, novel therapies created by HUTCHMED. Orpathys® is the only targeted medicine approved for these biomarker-selected patients in the Mainland. Sulanda®’s two recent approvals make it the first-ever drug launched to counter neuroendocrine tumours regardless of tumour origin, and approvals are also being sought in major jurisdictions such as the US and Europe.  

ESDlife had a very successful awards season in 2020 during a challenging year for the retail, public services, banking and finance, and insurance industries. The company won a Gold Award for Best AI Solution at the DigiZ Awards 2020 and a Gold Award for Best Loyalty Programme at The Loyalty and Engagement Awards 2020. It also won a range of other awards in mobile and apps, customer loyalty, fintech, design and retail.

Guangzhou Aircraft Maintenance Engineering Company (GAMECO) has expanded its aircraft maintenance operations to the newest airport in the nation’s capital, Beijing. GAMECO has recently been awarded approval from the Federal Aviation Administration and the European Aviation Safety Agency to conduct line maintenance and heavy maintenance. GAMECO’s operations hangar is Asia’s largest, and can hold up to five wide-body plus three narrow-body aircraft (or 12 narrow-body aircraft) at the same time.